Simultaneous parasympathetic and sympathetic activation reveals altered autonomic control of heart rate, vascular tension, and epinephrine release in anesthetized hypertensive rats

Frontiers in Neurology

Volumn NOV, Issue , 2011, Pages

  Berg, Torill ^a   Jensen, Jørgen ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b NORWEGIAN SCHOOL OF SPORT SCIENCES   (Norway)

Author keywords

4 aminopyridine; Adrenal; Epinephrine; Heart rate; Norepinephrine; Parasympathetic nerves; Sympathetic nerves; Total peripheral vascular resistance

Indexed keywords

EID: 84865843501     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2011.00071     Document Type: Article

References (33)

1. Berg, T. (2002). Analysis of the pres-sor response to the K+ channel inhibitor 4-aminopyridine. Eur. J. Pharmacol. 452, 325-337.
2. Berg, T. (2003). The vascular response to the K+ channel inhibitor 4-aminopyridine in hypertensive rats. Eur. J. Pharmacol. 466, 301-310.
3. Berg, T. (2005). Increased counter-acting effect of eNOS and nNOSon an alpha(1)-adrenergic rise in total peripheral vascular resistance in spontaneous hypertensive rats. Cardiovasc. Res. 67, 736-744.
4. Berg, T., Degerman, E., and Tasken, K. (2009). Increased cAMP signaling can ameliorate the hypertensive con-dition in spontaneously hyperten-sive rats. J. Vasc. Res. 46, 25-35.
5. Berg, T., and Koteng, O. (1997). Sig-nalling pathways in bradykinin- and nitric oxide-induced hypotension in the normotensive rat; role of K+-channels. Br. J. Pharmacol. 121, 1113-1120.
6. Berg, T., Piercey, B. W., and Jensen, J. (2010). Role of beta 1-3-adrenoceptors in blood pressure control at rest and during tyramine-induced norepinephrine release in spontaneously hypertensive rats. Hypertension 55, 1224-1230.
7. Berg, T., Schøyen, H., Wassdal, I., Hull, R., Gerskowitch, V. P., and Toft, K. (1992). Characterization of a new kallikrein-like enzyme (KLP-S3) of the rat submandibular gland. Biochem. J. 281, 819-828.
8. Bjørnstad-Østensen, A., and Berg, T. (1994). The role of nitric oxide, adrenergic activation and kinin-degradation in blood pres-sure homeostasis following an acutekinin-induced hypotension. Br. J. Pharmacol. 113, 1567-1573.
9. Boehm, S., and Kubista, H. (2002). Fine tuning of sympathetic trans-mitter release via ionotropic and metabotropic presynaptic receptors. Pharmacol. Rev. 54, 43-99.
10. Borovikova, L. V., Ivanova, S., Nardi, D., Zhang,M.,Yang,H.,Ombrellino, M., and Tracey, K. J. (2000). Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inammation. Auton. Neurosci. 85, 141-147.
11. Esler, M., Rumantir, M., Kaye, D., Jen-nings, G., Hastings, J., Socratous, F., and Lambert, G. (2001). Sym-pathetic nerve biology in essential hypertension. Clin. Exp. Pharmacol. Physiol. 28, 986-989.
12. Feres, T., Borges, A. C., Silva, E. G., Paiva, A. C., and Paiva, T. B. (1998). Impaired function of alpha-2 adrenoceptors in smooth muscle of mesenteric arteries from spon-taneously hypertensive rats. Br. J. Pharmacol. 125, 1144-1149.
13. Freeman, R. (2006). Assessment of cardiovascular autonomic function. Clin. Neurophysiol. 117, 716-730.
14. Glover, W. E. (1982). The aminopy-ridines. Gen. Pharmacol. 13, 259-285.
15. Jensen, J., Ruzzin, J., Jebens, E., Brennesvik, E. O., and Knar-dahl, S. (2005). Improved insulin-stimulated glucose uptake and glycogen synthase activation in rat skeletal muscles after adrenaline infusion: role of glycogen con-tent and PKB phosphorylation. Acta Physiol. Scand. 184, 121-130.
16. Malinowska, B., and Schlicker, E. (1997). Further evidence for differences between cardiac atypical beta-adrenoceptors and brown adipose tissue beta3-adrenoceptors in the pithed rat. Br. J. Pharmacol. 122, 1307-1314.
17. Miralles, A., Asensio, V. J., and Garcia-Sevilla, J. A. (2002). Acute treat-ment with the cyclic antidepres-sant desipramine, but not uoxe-tine, increasesmembrane-associated G protein-coupled receptor kinases 2/3 in rat brain. Neuropharmacology 43, 1249-1257.
18. Mravec, B. (2011). Role of catecholamine-induced activa-tion of vagal afferent pathways in regulation of sympathoadrenal system activity: negative feedback loop of stress response. Endocr. Regul. 45, 37-41.
19. Noor, N., Patel, C. B., and Rockman, H. A. (2010). beta-Arrestin: a signaling molecule and potential therapeutic target for heart failure. J. Mol. Cell Cardiol. 51, 534-541.
20. Ørstavik, T. B., and Gautvik, K. M. (1977). Regulation of salivary kallikrein secretion in the rat sub-mandibular gland. Acta Physiol. Scand. 100, 33-44.
21. Palatini, P., and Julius, S. (1997). Asso-ciation of tachycardia with morbid-ity and mortality: pathophysiologi-cal considerations. J. Hum. Hyper-tens. 11(Suppl. 1), S19-S27.
22. Palatini, P., and Julius, S. (2009). The role of cardiac autonomic function in hypertension and cardiovascular disease. Curr. Hypertens. Rep. 11, 199-205.
23. Paskov,D. S.,Agoston, S., and Bowman, W. C. (1986). " 4-Aminopyridine hydrochloride (pymadin)," inHand-book of Experimental Pharmacol-ogy, ed. D. A. Karckevich (Springer: Berlin), 679-717.
24. Ridley, J. M., Milnes, J. T., Zhang, Y. H., Witchel, H. J., and Hancox, J. C. (2003). Inhibition of HERG K+ current and prolongation of the guinea-pig ventricular action poten-tial by 4-aminopyridine. J. Physiol. 549, 667-672.
25. Shafaroudi, M. M., McBride, M., Deighan, C., Wokoma, A., Macmil-lan, J., Daly, C. J., and McGrath, J. C. (2005). Two " knockout" mousemodels demonstrate that aor-tic vasodilatation is mediated via alpha2a-adrenoceptors located on the endothelium. J. Pharmacol. Exp. Ther. 314, 804-810.
26. Simmons, M. A., and Dun, N. J. (1984). Actions of 4-aminopyridine on mammalian ganglion cells. Brain Res. 298, 149-153.
27. Tamargo, J., Caballero, R., Gomez, R., Valenzuela, C., and Delpon, E. (2004). Pharmacology of cardiac potassiumchannels. Cardiovasc. Res. 62, 9-33.
28. Thrasher, T. N. (2005). Baroreceptors, baroreceptor unloading, and the long-termcontrol of blood pressure. Am. J. Physiol Regul. Integr. Comp. Physiol. 288, R819-R827.
29. Tjugen, T. B., Flaa, A., and Kjeld-sen, S. E. (2010). The prognos-tic signicance of heart rate for cardiovascular disease and hyper-tension. Curr. Hypertens. Rep. 12, 162-169.
30. Tomaselli, G. F., andMarban, E. (1999). Electrophysiological remodeling in hypertrophy and heart failure. Car-diovasc. Res. 42, 270-283.
31. Vargas, H. M., and Ringdahl, B. (1990). Centrally active antimuscarinic analogs of oxotremorine selec-tively block physostigmine-induced hypertension, but not peripheralmuscarinic vasodepression. J. Pharmacol. Exp. Ther. 253, 165-170.
32. Wassermann, O. (1971). Studies on the pharmacokinetics of bis-quaternary ammoniumcompounds. II. Autora-diographic studies on the distrib-ution of 3 H-hexamethonium in mice. Naunyn Schmiedebergs Arch. Pharmacol. 270, 419-427.
33. Zugck, C., Lossnitzer, D., Backs, J., Kris-ten, A., Kinscherf, R., and Haass, M. (2003). Increased cardiac norep-inephrine release in spontaneously hypertensive rats: role of presynaptic alpha-2A adrenoceptors. J. Hyper-tens. 21, 1363-1369.